GNMK
$5.64
Genmark Diagnostics
$.04
.71%
GNMK
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.16)
Revenue:  $27.32 Mil
Wednesday
Feb 5
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Guidance announcement made Wednesday, November 06, 2019
Latest EPS
Wednesday, November 06, 2019

What do you expect when GNMK reports earnings?
Beat
Meet
Miss

Where is GNMK's stock price going from here?
Up
Flat
Down
Stock chart of GNMK
Analysts
Summary of analysts' recommendations for GNMK
Score
Grade
Pivots
Resistance
$5.95
$5.85
$5.75

$5.65

Support
$5.54
$5.44
$5.34
Tweet
Growth
Description
GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor? XT-8 system is the second generation in GenMark Dx's eSensor? platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.
Peers
Edwards LifesciencesIntuitive SurgicalWright Medical GroupAlign TechnologyCryoLifeSTERISInvacareRTI SurgicalLakeland Industries